Brokerages Anticipate Ionis Pharmaceuticals, Inc. (IONS) Will Post Earnings of -$0.06 Per Share
Equities analysts expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to post ($0.06) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $0.29 and the lowest is ($0.36). Ionis Pharmaceuticals posted earnings per share of $0.21 during the same quarter last year, which indicates a negative year over year growth rate of 128.6%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.06) per share for the current year, with EPS estimates ranging from ($0.25) to $0.22. For the next fiscal year, analysts anticipate that the business will report earnings of $0.40 per share, with EPS estimates ranging from ($1.10) to $2.91. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Ionis Pharmaceuticals.
A number of brokerages have recently issued reports on IONS. Morgan Stanley boosted their target price on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 8th. Stifel Nicolaus reissued a “hold” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, September 12th. Evercore ISI began coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $65.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. Finally, Jefferies Group LLC reaffirmed an “underperform” rating and set a $18.00 price objective (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $50.31.
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) traded up $0.76 during trading on Friday, hitting $55.88. 699,400 shares of the stock were exchanged, compared to its average volume of 1,512,485. The company has a market capitalization of $6,973.57, a PE ratio of 372.53 and a beta of 2.90. Ionis Pharmaceuticals has a 52 week low of $37.26 and a 52 week high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.
In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 27,500 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $52.89, for a total transaction of $1,454,475.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stanley T. Crooke sold 15,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $52.00, for a total value of $780,000.00. Following the transaction, the chief executive officer now directly owns 43,014 shares of the company’s stock, valued at approximately $2,236,728. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,636 shares of company stock valued at $5,723,915. Insiders own 2.13% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of IONS. Prudential Financial Inc. raised its stake in Ionis Pharmaceuticals by 36.4% during the first quarter. Prudential Financial Inc. now owns 8,241 shares of the company’s stock worth $331,000 after acquiring an additional 2,200 shares in the last quarter. Teachers Advisors LLC raised its stake in Ionis Pharmaceuticals by 6.3% during the first quarter. Teachers Advisors LLC now owns 131,656 shares of the company’s stock worth $5,293,000 after acquiring an additional 7,846 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Ionis Pharmaceuticals by 211.2% in the first quarter. Legal & General Group Plc now owns 40,536 shares of the company’s stock valued at $1,630,000 after buying an additional 27,512 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Ionis Pharmaceuticals by 75.0% in the first quarter. Dimensional Fund Advisors LP now owns 170,316 shares of the company’s stock valued at $6,847,000 after buying an additional 72,975 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Ionis Pharmaceuticals by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 312,963 shares of the company’s stock valued at $12,582,000 after buying an additional 3,688 shares during the period. 88.98% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/brokerages-anticipate-ionis-pharmaceuticals-inc-ions-will-post-earnings-of-0-06-per-share/1701180.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.